製品: VIPR2 Antibody
カタログ: DF5173
タンパク質の説明: Rabbit polyclonal antibody to VIPR2
アプリケーション: WB IHC IF/ICC
反応性: Human, Mouse, Rat
予測: Pig, Bovine, Horse, Sheep, Rabbit, Dog
分子量: 49 KD; 49kD(Calculated).
ユニプロット: P41587
RRID: AB_2837522

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:500-1:1000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
予測:
Pig(100%), Bovine(100%), Horse(80%), Sheep(100%), Rabbit(80%), Dog(80%)
クローナリティ:
Polyclonal
特異性:
VIPR2 Antibody detects endogenous levels of total VIPR2.
RRID:
AB_2837522
引用形式: Affinity Biosciences Cat# DF5173, RRID:AB_2837522.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ/展開

Helodermin-preferring VIP receptor; PACAP type III receptor; PACAP-R-3; PACAP-R3; Pituitary adenylate cyclase-activating polypeptide type III receptor; Vasoactive intestinal polypeptide receptor 2; VIP Receptor 2; VIP-R-2; Vipr2; VIPR2_HUMAN; VPAC2 receptor;

免疫原

免疫原:
Uniprot:
遺伝子(ID):
発現特異性:
P41587 VIPR2_HUMAN:

Expressed in CD4+ T-cells, but not in CD8+ T-cells. Expressed in the T-cell lines Jurkat, Peer, MOLT-4, HSB, YT and SUP-T1, but not in the T-cell lines HARRIS and HuT 78.

タンパク質配列:
MRTLLPPALLTCWLLAPVNSIHPECRFHLEIQEEETKCAELLRSQTEKHKACSGVWDNITCWRPANVGETVTVPCPKVFSNFYSKAGNISKNCTSDGWSETFPDFVDACGYSDPEDESKITFYILVKAIYTLGYSVSLMSLATGSIILCLFRKLHCTRNYIHLNLFLSFILRAISVLVKDDVLYSSSGTLHCPDQPSSWVGCKLSLVFLQYCIMANFFWLLVEGLYLHTLLVAMLPPRRCFLAYLLIGWGLPTVCIGAWTAARLYLEDTGCWDTNDHSVPWWVIRIPILISIIVNFVLFISIIRILLQKLTSPDVGGNDQSQYKRLAKSTLLLIPLFGVHYMVFAVFPISISSKYQILFELCLGSFQGLVVAVLYCFLNSEVQCELKRKWRSRCPTPSASRDYRVCGSSFSRNGSEGALQFHRGSRAQSFLQTETSVI

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Bovine
100
Sheep
100
Horse
80
Dog
80
Rabbit
80
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P41587 基板として

Site PTM Type Enzyme
S409 Phosphorylation
S415 Phosphorylation
S429 Phosphorylation

研究背景

機能:

This is a receptor for VIP as well as PACAP-38 and -27, the activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Can be coupled to phospholipase C.

細胞の位置付け:

Cell membrane>Multi-pass membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Expressed in CD4+ T-cells, but not in CD8+ T-cells. Expressed in the T-cell lines Jurkat, Peer, MOLT-4, HSB, YT and SUP-T1, but not in the T-cell lines HARRIS and HuT 78.

タンパク質ファミリー:

Belongs to the G-protein coupled receptor 2 family.

研究領域

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Neuroactive ligand-receptor interaction.

参考文献

1). Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4+ type 9 helper T cells and the VIP–VPAC2 signalling pathway. PHARMACEUTICAL BIOLOGY, 2021 (PubMed: 34493162) [IF=3.8]

Application: IF/ICC    Species: Mice    Sample: lung tissues

Figure 9. Effects of M-BYF on VPAC2 expression and VPAC2+CD90+ cells in OVA-induced asthmatic mice. (A) Representative immunofluorescent staining images of VPAC2 and VPAC2+CD90+ cells. VPAC2 staining as shown in red. CD90 staining as shown in green. Scale bar: 50 µm and 20 µm. (B, C) The protein expression of VPAC2 in lungs was detected by western blot and densitometric analysis was performed. M-BYF reduced the expression of VPAC2 protein in lungs of asthmatic mice as compared with the Model group (D) Quantification of VPAC2+CD90+ cells showed that M-BYF reduced percentage of VPAC2+CD90+ cells in lungs of asthmatic mice as compared with the Model group. Four non-consecutive sections from each animal were averaged and compared among experimental groups; n = 3 in each group. Data are represented as mean ± S.E.M. (ΔΔΔp < 0.001, Δp < 0.05 compared with the Control group; ***p < 0.001, **p < 0.01 and *p < 0.05 compared with the Model group; #p < 0.05 compared with the dexamethasone treated group.)

Application: WB    Species: Mice    Sample: lung tissues

Figure 9. Effects of M-BYF on VPAC2 expression and VPAC2+CD90+ cells in OVA-induced asthmatic mice. (A) Representative immunofluorescent staining images of VPAC2 and VPAC2+CD90+ cells. VPAC2 staining as shown in red. CD90 staining as shown in green. Scale bar: 50 µm and 20 µm. (B, C) The protein expression of VPAC2 in lungs was detected by western blot and densitometric analysis was performed. M-BYF reduced the expression of VPAC2 protein in lungs of asthmatic mice as compared with the Model group (D) Quantification of VPAC2+CD90+ cells showed that M-BYF reduced percentage of VPAC2+CD90+ cells in lungs of asthmatic mice as compared with the Model group. Four non-consecutive sections from each animal were averaged and compared among experimental groups; n = 3 in each group. Data are represented as mean ± S.E.M. (ΔΔΔp < 0.001, Δp < 0.05 compared with the Control group; ***p < 0.001, **p < 0.01 and *p < 0.05 compared with the Model group; #p < 0.05 compared with the dexamethasone treated group.)

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.